Neurovascular Dysfunction Biochip
The Neurovascular Dysfunction Biochip gives clinicians a greater understanding of conditions involving disruption of the blood-brain barrier and associated vasculature. The biomarker panel is currently useful as a research tool for disease areas such as Epilepsy, Stroke Research, Brain Inflammation, Parkinson’s Disease, Alzheimer’s Disease, Down Syndrome, Brain Injury and Delirium.
Biochip Performance
Biomarker | Measuring Range |
Glutathione S-transferase Pi (GSTPi) | 0 - 200 ng/mL |
Parkinson Disease Protein 7 (PARK7) | 0 - 100 ng/mL |
Nucleoside Diphosphate Kinase A (NDKA) | 0 - 250 ng/mL |
Glial Fibrillary Acidic Protein (GFAP) | 0 - 100 ng/mL |
Fatty Acid Binding Protein 3 (FABP3) | 0 - 150 ng/mL |
Interleukin-6 (IL-6) | 0 - 500 pg/mL |
Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) | 0 - 25 ng/mL |
D-Dimer | 0 - 5000 ng/mL |
Benefits of the MultiSTAT
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.